公开(公告)号：EP4389114A1

公开(公告)日：2024-06-26

申请号：EP22857878.7

申请日：2022-08-18

Applicant: Zhuhai United Laboratories Co., Ltd.

Inventor： SHEN, Meiyue ,  MU, Liwei ,  YU, Tingting ,  HE, Yujun ,  SU, Chong ,  GAO, Peng ,  WANG, Zheng ,  WANG, Degang

IPC: A61K9/06 ,  A61K31/519 ,  C07D471/04 ,  C07D487/00 ,  A61P17/00 ,  A61P17/06 ,  A61P17/14

CPC classification number: A61K9/06 ,  A61K31/519 ,  A61P17/00 ,  A61P17/06 ,  A61P17/14 ,  C07D471/04 ,  C07D487/00

Abstract: The present application relates to the field of pharmaceutical preparations and relates to [1,2,4] triazolo [1,5-a] pyridine compounds and their isomers or pharmaceutically acceptable salts or their crystal forms, as well as local topical preparations and their applications in skin diseases. Specifically, it relates to a local topical formulations of compound (S)-N-(5-(2-(2,2-difluorocyclopropanecarbonyl)-2-nitrospiro[3.5]non-7-yl)-[1,2,4-triazole[1,5-a]pyridine-2-yl) cyclopropaneformamide and its isomers or pharmaceutically acceptable salts or crystal forms, and their applications in skin diseases. The preferred skin diseases include psoriasis, atopic dermatitis, vitiligo, lupus erythematosus, alopecia areata, eczema, contact dermatitis, urticaria, pompholyxs, dermatomyositis, scleroderma, acne, and seborrheic dermatitis.

公开(公告)号：EP4319743A1

公开(公告)日：2024-02-14

申请号：EP22785648.1

申请日：2022-04-07

Applicant: Abbvie Inc.

Inventor： MATTEI, Alessandra

IPC: A61K31/395 ,  A61K31/495 ,  A61K31/4985 ,  C07D487/00 ,  C07D487/12 ,  C07D487/14

公开(公告)号：EP3842431B1

公开(公告)日：2023-12-27

申请号：EP19852944.8

申请日：2019-08-23

Inventor： MAO, Weiwei ,  QIAN, Wenyuan ,  ZHENG, Xuejian ,  HU, Guoping ,  WEI, Changqing ,  LI, Jian ,  CHEN, Shuhui

IPC: C07D471/04 ,  C07D487/00 ,  A61K31/437 ,  A61P19/02

公开(公告)号：EP3818115B1

公开(公告)日：2023-11-22

申请号：EP19737194.1

申请日：2019-07-04

Inventor： DE BOER, Johannes Wietse ,  HAGE, Ronald ,  MAAIJEN, Karin ,  ROELOFSEN, Yfranka Petronella Areke

IPC: C09D167/08 ,  C08K5/00 ,  C07D487/00 ,  C07D255/02 ,  C08G63/83

公开(公告)号：EP3279316B1

公开(公告)日：2023-09-20

申请号：EP17192973.0

申请日：2012-11-20

Inventor： GALVE-ROPERH, Ismael ,  GUZMÁN PASTOR, Manuel ,  DÍAZ-ALONSO, Javier ,  AGUADO SANCHEZ, Tania ,  PARAÍSO LUNA, Juan

IPC: C12N5/079 ,  C07D487/00 ,  A61K31/352 ,  A61K31/4355 ,  C07D401/12 ,  A61K31/343 ,  A61K35/30 ,  C12N5/0793 ,  A61K31/4439

公开(公告)号：EP4151221A1

公开(公告)日：2023-03-22

申请号：EP21804833.8

申请日：2021-05-14

Applicant: Fujian Akeylink Biotechnology Co., Ltd.

Inventor： WU, Wenqiang ,  ZHANG, Dong ,  MA, Zhiqiang ,  ZHOU, Yixin ,  MAO, John ,  JIANG, Zhigan ,  WANG, Jing ,  HE, Haiying

IPC: A61K31/55 ,  A61K31/33 ,  A61K31/395 ,  A61K31/40 ,  A61K31/5365 ,  C07D487/00 ,  C07D471/04 ,  C07D498/04 ,  A61P1/16 ,  A61P31/20

Abstract: A combination comprising a tricycle compound and use thereof in the preparation of a medicament for treating HBV The combination is a combination of a compound of formula (I) or a pharmaceutically acceptable salt thereof and any one drug in the following groups a-c: a. a hepatitis B surface antigen inhibitor, b. a reverse transcriptase inhibitor, and c. a hepatitis B surface antigen inhibitor and a reverse transcriptase inhibitor.

公开(公告)号：EP4105214A1

公开(公告)日：2022-12-21

申请号：EP20919255.8

申请日：2020-02-13

Applicant: Zhuhai United Laboratories Co., Ltd

Inventor： WANG, Shuai ,  WANG, Degang ,  WU, Shouting ,  YU, Tingting ,  FANG, Miao ,  MU, Liwei ,  FANG, Liang

IPC: C07D471/04 ,  C07D487/00 ,  A61K31/437 ,  A61P19/02 ,  A61P17/06 ,  A61P37/06 ,  A61P37/08

Abstract: The invention discloses an application of JAK inhibitors [1,2,4]triazolo[1,5-a]pyridine compounds in the preparation and treatment of autoimmune, inflammatory or allergic diseases, transplantation rejection and other diseases. The JAK inhibitors [1,2,4]triazolo[1,5-a]pyridine compounds include the compounds shown in formula (I), their isomers or their pharmaceutically acceptable salts:

the JAK inhibitors of the present invention have good efficacy in animal model tests of autoimmune, inflammatory or allergic diseases, especially in animal in vivo efficacy evaluation tests of inflammatory bowel disease and allergic dermatitis.

公开(公告)号：EP4105207A1

公开(公告)日：2022-12-21

申请号：EP21754125.9

申请日：2021-02-08

Applicant: Betta Pharmaceuticals Co., Ltd

Inventor： LIU, Xiangyong ,  QIU, Changyong ,  LIU, Mengqiang ,  SONG, Xiaodong ,  SHEN, Qichao ,  DU, Guolong ,  SHENG, Haitong ,  DING, Lieming ,  WANG, Jiabing

IPC: C07D401/12 ,  C07D471/10 ,  C07D487/00 ,  C07D241/02 ,  A61K31/66 ,  A61K31/675 ,  A61P35/00

Abstract: The present invention relates to a compound of formula (I), a method for using the compound as an EGFR inhibitor, and a pharmaceutical composition comprising the compound. The compound can be used for treatment, prevention or alleviation of diseases or disorders such as cancer or infection.

公开(公告)号：EP3854797A1

公开(公告)日：2021-07-28

申请号：EP19853095.8

申请日：2019-08-23

Applicant: Fujian Cosunter Pharmaceutical Co., Ltd.

Inventor： WANG, Jing ,  JIANG, Zhigan ,  HE, Haiying ,  YANG, Yaxun

IPC: C07D487/00 ,  A61K31/33 ,  A61K31/395 ,  A61K31/40 ,  A61P1/16

Abstract: Disclosed are crystal form A and crystal form B of a compound represented by formula (I), and application thereof in the preparation of medicaments for treating HBV-related diseases.

公开(公告)号：EP3810134A1

公开(公告)日：2021-04-28

申请号：EP19823013.8

申请日：2019-06-18

Applicant: Celecor Therapeutics, Inc.

Inventor： JOSHI, Yatindra

IPC: A61K31/435 ,  A61K31/4353 ,  A61K31/505 ,  C07D471/00 ,  C07D487/00 ,  C07D513/04